Citadel Advisors
SION

Citadel Advisors’s Sionna Therapeutics SION Stock Holding History

Citadel Advisors’s Portfolio SION Stock Details SION Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$46.8M Buy
1,166,931
+79,606
+7% +$3.04M 0.01% 1423
2025
Q4 		$44.7M Buy
1,087,325
+1,051,402
+2,927% +$39.9M 0.01% 1526
2025
Q3 		$1.06M Sell
35,923
-93,989
-72% -$2.04M ﹤0.01% 7421
2025
Q2 		$2.25M Sell
129,912
-196,588
-60% -$2.58M ﹤0.01% 5483
2025
Q1 		$3.42M Buy
+326,500
New +$5.33M ﹤0.01% 4540

Other funds holding SION

RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
TGA
TPG GP A Fort Worth, Texas $3.68B AUM 14.99% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Citadel Advisors's SION Position: Q1 2026 in Review

Citadel Advisors increased its Sionna Therapeutics (SION) stake by 7.3% in Q1 2026, buying an estimated $3.04M and bringing the position to 1,166,931 shares worth $46.8M. The position accounts for 0.01% of the portfolio, ranked #1423.

Citadel Advisors first reported a position in SION in Q1 2025 and has held it in 5 quarters since. 122 funds tracked by Wall St. Rank hold SION as of Q1 2026.

  • Citadel Advisors held 1,166,931 shares of Sionna Therapeutics worth $46.8M as of Q1 2026.
  • Citadel Advisors bought 79,606 Sionna Therapeutics shares in Q1 2026, an estimated $3.04M.
  • Sionna Therapeutics made up 0.01% of Citadel Advisors's portfolio in Q1 2026, its #1423 holding.
  • Citadel Advisors first reported a position in Sionna Therapeutics in Q1 2025 and has held it in 5 quarters since.
  • 122 funds tracked by Wall St. Rank held Sionna Therapeutics as of Q1 2026.

Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.